Viral Clearance Market Report 2026

The viral clearance market size has grown rapidly in recent years. It will grow from $0.96 billion in 2025 to $1.12 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to limited viral clearance technologies, increasing viral contamination concerns in biologics, reliance on conventional filtration methods, growing regulatory scrutiny, expansion of pharmaceutical and biotech manufacturing pipelines.

The viral clearance market size is expected to see rapid growth in the next few years. It will grow to $2.06 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to development of next-generation viral inactivation methods, rising adoption of nanofiltration and membrane chromatography, increasing biologics and gene therapy production, integration of automation in viral clearance workflows, growing investment in viral detection assay development. Major trends in the forecast period include increasing adoption of advanced viral detection and inactivation methods, rising demand for safe and virus-free vaccines and therapeutics, expansion of cellular and gene therapy products requiring viral clearance, integration of high-efficiency filtration and nanofiltration technologies, growing outsourcing to contract research organizations for viral clearance services.

The mounting prevalence of chronic diseases is set to boost the viral clearance market ahead. Chronic diseases are persistent health issues that emerge gradually and endure for months or years, typically needing ongoing oversight or intervention. Their global uptick largely arises from aging demographics, as enhanced healthcare and living conditions extend lifespans, spurring more age-linked ailments like heart disease, diabetes, arthritis, and cancer. Viral clearance plays a vital role in crafting biologics and gene therapies for these conditions, guaranteeing their purity and reliability. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, indicated over half a billion people worldwide had diabetes, with projections doubling to 1.3 billion by 2050. Therefore, the rising prevalence of chronic diseases is driving the growth of the viral clearance market.

Key companies in the viral clearance market are advancing novel tools like next-generation virus removal filters to heighten viral safety and streamline biopharma production. Next-generation virus removal filters are sophisticated filters engineered to strip viruses from biopharmaceuticals, bolstering safety, accelerating flow rates, and lifting manufacturing yields. For instance, in October 2024, Asahi Kasei Medical Co., Ltd., a Japan-based medical and bioprocess solutions company, debuted its next-generation Planova FG1 virus-removal filter, delivering about seven-times the flux of Planova BioEX to cut filtration duration, lower virus leakage chances, and sustain robust protein and virus elimination sans prefilter; the FG1 aligns with standard CIP/SIP protocols, hit mass production in compact sizes, and eyes larger variants for scaling, higher volumes, and quicker cycles for biomanufacturers.

In August 2024, Merck Group, a Germany-based healthcare company, purchased Mirus Bio LLC for $600 million. This acquisition elevates Merck's viral vector production prowess with top-tier transfection tech, sharpening integrated offerings for the booming gene therapy sector. Mirus Bio LLC is a US-based pharmaceutical company that specializes in transfection reagents for viral clearance.

Major companies operating in the viral clearance market are Merck Group, Thermo Fisher Scientific Inc., Asahi Kasei Corporation, SGS SA, Eurofins Scientific Inc., Lonza Group AG, WuXi AppTec, Catalent Biologics, Charles River Laboratories, Nelson Labs, Pall Corporation, Sartorius AG, Creative Biolabs, Texcell SA, Vironova AB.

North America was the largest region in the viral clearance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral clearance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral clearance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the viral clearance market by increasing costs for imported filtration membranes, chromatography resins, viral inactivation reagents, and analytical instruments. Segments such as viral inactivation and detection methods are most affected, particularly in North America, Europe, and Asia-Pacific regions including China and India. This has led to higher operational costs and potential delays in biologics and gene therapy production. On the positive side, tariffs have encouraged local manufacturing, innovation in viral clearance technologies, and investment in domestic production capacities.

The viral clearance market research report is one of a series of new reports that provides viral clearance market statistics, including viral clearance industry global market size, regional shares, competitors with a viral clearance market share, detailed viral clearance market segments, market trends and opportunities, and any further data you may need to thrive in the viral clearance industry. This viral clearance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral clearance is the process of identifying, removing, or inactivating viruses from biological products to ensure they are free from viral contamination. This process involves techniques such as filtration, chemical treatment, and heat inactivation. Its primary goal is to guarantee the safety and purity of products by reducing the risk of virus transmission.

The main methods of viral clearance include viral removal, viral inactivation, and viral detection. These techniques are designed to eliminate potential viral contaminants from biological products. They are applied across various areas, including vaccines and therapeutics, blood and blood products, cellular and gene therapy products, tissue-based products, and others, serving end users such as pharmaceutical and biotechnology companies, contract research organizations (CROs), academic research institutes, and others.

The viral clearance market consists of revenues earned by entities by providing services such as viral removal and inactivation testing, validation studies, and regulatory consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral clearance market also includes sales of viral filters, reagents, and specialized clearance equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.